Search

Displaying results 271 - 280 of 4584 in total
  1. Drug

    Mycophenolic acid

    go.drugbank.com/drugs/DB01024
    ApprovedInvestigational

    [A249175] This regimen can be used in place of the older anti-proliferative [azathioprine] due to its stronger immunosuppressive potency. … [A249180,A249185] Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an effort to improve upper gastrointestinal adverse events by delaying mycophenolic acid release until

  2. Indication

    Gastroesophageal Reflux Disease With Esophagitis

    go.drugbank.com/conditions/DBCOND0125782
    Drugs: Simethicone
    Synonyms: Gastro-esophageal reflux disease with esophagitis, without bleeding
  3. Indication

    Symptomatic Epilepsy

    go.drugbank.com/conditions/DBCOND0119818
    Drugs: Gamma-amino-beta-hydroxybutyric acid
    Synonyms: Epilepsy, unspecified, not intractable, without status epilepticus
  4. Drug

    Conjugated estrogens

    go.drugbank.com/drugs/DB00286
    ApprovedInvestigational

    Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble. … The conjugated estrogens are noncrystalline mixtures of purified female sex hormones obtained either by its isolation from the urine of pregnant mares or by synthetic generation from vegetal material.

  5. Drug

    Cyanocobalamin

    go.drugbank.com/drugs/DB00115
    ApprovedInvestigationalNutraceutical

    This drug was initially approved by the FDA in 1942 [FDA label]. … This vitamin is produced naturally by bacteria [A175276], and is necessary for DNA synthesis and cellular energy production.

    Mixtures: Vita-B, Liqui Vita
  6. Drug

    Gedatolisib

    go.drugbank.com/drugs/DB11896
    ApprovedInvestigational

    [L63927] Gedatolisib was approved by the FDA on July 14, 2026, in combination with [fulvestrant], with or without [palbociclib], for adults with HR-positive, HER2-negative locally advanced or metastatic … breast cancer without a PIK3CA mutation detected, following progression on or after at least one line of endocrine therapy in the metastatic setting.

  7. Indication

    Neoplasms

    go.drugbank.com/conditions/DBCOND0027948
    Drugs: Betamethasone phosphate · Hydrocortisone acetate · Prednisolone phosphate · Thiotepa
    Synonyms: Malignant neoplasm without specification of site, [X]Malignant neoplasm without specification of site (disorder)
  8. Drug

    Insulin icodec

    go.drugbank.com/drugs/DB16693
    ApprovedInvestigational

    [L50758,A263818] Insulin icodec was approved by Health Canada in March 2024 for the treatment of adult patients with type 1 or 2 diabetes mellitus,[L50758] and was subsequently approved by the EMA in

  9. Drug

    Camizestrant

    go.drugbank.com/drugs/DB19218
    ApprovedInvestigational

    [L64094,L64107] It binds the ligand binding domain of ERα, antagonizing ERα encoded by both wild-type and mutated *ESR1* and inducing proteasome-dependent degradation of the receptor without agonizing … [L64094,L64107] Patients are selected for treatment on the basis of an *ESR1* mutation detected by circulating tumor DNA testing during first-line endocrine therapy, before radiographic disease progression

  10. Drug

    Emicizumab

    go.drugbank.com/drugs/DB13923
    ApprovedInvestigational

    [A31279, L1016] It was created by Chugai Pharmaceuticals Co. Ltd. and co-developed with Roche and Genentech.[L1015] … The ability of Emicizumab to bind to all these three different factors allows it to overcome immunogenicity and unstable hemostatic efficacy produced by previous Factor VII agents.